Cargando…
Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials
Duchenne muscular dystrophy (DMD) is a serious, rare genetic disease, affecting primarily boys. It is caused by mutations in the DMD gene and is characterized by progressive muscle degeneration that results in loss of function and early death due to respiratory and/or cardiac failure. Although limit...
Autores principales: | Chamberlain, Jeffrey S., Robb, Melissa, Braun, Serge, Brown, Kristy J., Danos, Olivier, Ganot, Annie, Gonzalez-Alegre, Pedro, Hunter, Nina, McDonald, Craig, Morris, Carl, Tobolowsky, Mark, Wagner, Kathryn R., Ziolkowski, Olivia, Duan, Dongsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210223/ https://www.ncbi.nlm.nih.gov/pubmed/36694468 http://dx.doi.org/10.1089/hum.2022.190 |
Ejemplares similares
-
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
por: Le Guiner, Caroline, et al.
Publicado: (2017) -
Microdystrophin Gene Addition Significantly Improves Muscle Functionality and Diaphragm Muscle Histopathology in a Fibrotic Mouse Model of Duchenne Muscular Dystrophy
por: Cernisova, Viktorija, et al.
Publicado: (2023) -
Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987) -
Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy
por: Biggar, W. Douglas, et al.
Publicado: (2022) -
Improved transduction of canine X-linked muscular dystrophy with rAAV9-microdystrophin via multipotent MSC pretreatment
por: Hayashita-Kinoh, Hiromi, et al.
Publicado: (2020)